Search
This lunch is for all ANCO and MOASC MD, Fellows, and Prospective MD and Fellow Members who are attending the ASCO Annual Meeting. This meeting is for practitioners only; industry representatives may not attend.
Lunch will be served from 11:30am - 1:30pm at the Hyatt Regency McCormick Place in the Regency CD room. Come by whenever you can!
This is not an official event of the 2026 ASCO Annual Meeting. It is not sponsored, endorsed, or accredited by ASCO or Conquer Cancer®, the ASCO Foundation. Please let us know if you plan to attend by Monday, May 18th.
ANCO wants to take you out to the ballgame! Join us at Oracle Park on Friday, August 14th, for an evening of camaraderie, connection, and San Francisco Giants! This exclusive, practitioner-only event is curated specifically for our member community to network, relax, and enjoy the game in style. Spend Friday night unwinding with colleagues, then join us Saturday for ANCO’s ASCO26 Highlights (complimentary to members) for a high-impact review distilling the latest practice-changing data into actionable clinical insights. The Game Plan:
Ticket Info: Your digital tickets will be emailed directly to you on August 7th (one week before the game). Please ensure your email address we have in our database is current.
Join us for ANCO’s ASCO26 Highlights, a high-impact review designed to present the most practice-changing data from the world’s premier oncology stage into actionable clinical insights.
This isn't just a summary—it’s a roadmap for the future of oncology. Our expert faculty will bridge the gap between late-breaking research and your practice, placing every advancement into the context of immediate clinical utility.
Industry Registration
Please read below to understand ANCO's industry registration waitlist process.
At ANCO, we strive to foster meaningful connections and facilitate valuable interactions among participants at our meetings. To ensure a fair distribution of attendance and provide an opportunity for various stakeholders to participate and engage with the cancer care community at large, industry registrations for our meetings are intentionally limited. Industry Registrations are limited to a maximum of three representatives per company, from companies who are not exhibiting at the meeting, with a maximum of 15 companies.
This policy is contingent upon meeting registrations and venue capacity. If we do have additional space, we will accept more representatives.
How does the ANCO Industry Registration waitlist approval process work?
Clinical trials are the engine of progress in oncology, offering the most promising potential therapies and, often, the treatment of choice for cancer patients. However, navigating the landscape of trial enrollment—especially for genitourinary malignancies—requires a specialized, collaborative, and patient-centered approach that is rarely incorporated in standard continuing medical education.
We invite you to join us for an innovative one-day educational meeting that bridges this critical gap. This forum convenes leading academic and community clinicians and researchers to enhance collaboration, share cutting-edge science, and strategize on best practices for clinical trial participation in kidney, bladder, and prostate cancer.
Registration will open in spring 2026.
What is ANCO’s Industry Registration policy?
At ANCO, we strive to foster meaningful connections and facilitate valuable interactions among participants at our meetings. To ensure a fair distribution of attendance and provide an opportunity for various stakeholders to participate and engage with the cancer care community at large, industry registrations for our meetings are intentionally limited.Industry Registrations are limited to a maximum of three representatives per company, from companies who are not exhibiting at the meeting, with a maximum of 15 companies.
Precision oncology promises to improve the outcomes of patients through broad molecular diagnostic profiling and individualized treatment recommendations. Recent FDA approvals of new cancer treatments that are based on molecular tumor features and not disease type underscore the relevance of this approach.
However, the landscape of available diagnostic technologies and targeted drugs is rapidly changing, making it extremely difficult for practicing oncologists and related professionals to stay up to date and to offer their patients the best molecular diagnostic approach possible. By attending this meeting, clinicians will be informed on cutting edge technologies and their optimal clinical application.
Apply to Become a Member
4225 Solano Ave, #764 Napa, CA 94558 Phone (415) 472-3960
Association of Northern California Oncologists © 2025 | Privacy Policy | Disclaimer